162 related articles for article (PubMed ID: 19458051)
1. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Ma W; Kantarjian H; Bekele B; Donahue AC; Zhang X; Zhang ZJ; O'Brien S; Estey E; Estrov Z; Cortes J; Keating M; Giles F; Albitar M
Clin Cancer Res; 2009 Jun; 15(11):3820-6. PubMed ID: 19458051
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Ma W; Kantarjian H; O'Brien S; Jilani I; Zhang X; Estrov Z; Ferrajoli A; Keating M; Giles F; Albitar M
Cancer; 2008 Mar; 112(6):1306-12. PubMed ID: 18224667
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.
Ma W; Kantarjian H; Zhang X; Wang X; Estrov Z; O'Brien S; Albitar M
Leuk Res; 2011 Apr; 35(4):526-33. PubMed ID: 20951430
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
[TBL] [Abstract][Full Text] [Related]
5. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Amin HM; Yang Y; Shen Y; Estey EH; Giles FJ; Pierce SA; Kantarjian HM; O'Brien SM; Jilani I; Albitar M
Leukemia; 2005 Sep; 19(9):1567-72. PubMed ID: 16049515
[TBL] [Abstract][Full Text] [Related]
6. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
Verstovsek S; Kantarjian H; Estey E; Aguayo A; Giles FJ; Manshouri T; Koller C; Estrov Z; Freireich E; Keating M; Albitar M
Leukemia; 2001 Aug; 15(8):1165-70. PubMed ID: 11480557
[TBL] [Abstract][Full Text] [Related]
7. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome.
Verstovsek S; Kantarjian H; Aguayo A; Manshouri T; Freireich E; Keating M; Estey E; Albitar M
Br J Haematol; 2001 Aug; 114(2):290-5. PubMed ID: 11529846
[TBL] [Abstract][Full Text] [Related]
8. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
[TBL] [Abstract][Full Text] [Related]
9. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Albitar M; Johnson M; Do KA; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles FJ
Leukemia; 2007 Mar; 21(3):480-8. PubMed ID: 17215857
[TBL] [Abstract][Full Text] [Related]
10. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
[TBL] [Abstract][Full Text] [Related]
14. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute myeloid leukemia.
Aul C; Gattermann N; Schneider W
Blood; 1992 Aug; 80(3):625-33. PubMed ID: 1638020
[TBL] [Abstract][Full Text] [Related]
16. Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias.
Ostrowska H; Hempel D; Holub M; Sokolowski J; Kloczko J
Clin Biochem; 2008 Nov; 41(16-17):1377-83. PubMed ID: 18773885
[TBL] [Abstract][Full Text] [Related]
17. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
18. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
19. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of chromosome karyotype between myelodysplastic syndrome and acute leukemia patients confirmed at the same period].
Jiang M; Wen BZ; Li L; Chen S; Cheng H; Hao JP; Chen R; Wang L; Zhao F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):387-92. PubMed ID: 24763010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
